HUMA
Humacyte, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.59
−0.74%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
Market Cap
$164.35M
MomentumView details →
1D Return
−0.74%
YTD Return
−37.47%
RSI (14)
43.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
Market Cap
$164.35M
RSI (14)
43.9
MomentumView details →
1D Return
−0.74%
YTD Return
−37.47%
SummaryUpdated Jun 1, 2026
Humacyte, Inc. (NASDAQ:HUMA) is a clinical-stage biotechnology company founded in 2004 and headquartered in Durham, North Carolina. The company went public in December 2020 and specializes in developing bioengineered human tissues for vascular repair and replacement applications. Humacyte has achieved its first commercial milestone with the FDA approval of its flagship product Symvess in 2024 for treating extremity vascular trauma, marking the transition from a pure research and development company to one generating initial commercial revenues.
Similar companies
Latest newsMore news →
Humacyte, Inc. reported Q2 2026 revenue of $0.4 million and a net loss of $36.8 million, with diluted EPS of -$0.16.24d agoHumacyte, Inc. (HUMA) shares rose 2.33% to close at $0.73 in the recent trading session.30d agoHumacyte announced that the FDA accepted its IND application for a first-in-human clinical study of CTEV for coronary artery bypass grafting.39d ago